Lowering myeloid GRK2 protein could prevent this vicious cycle from establishing and thus stop vascular dysfunction by preventing, on the one hand, the pro-inflammatory shift and, on the other, the increased NADPH oxidase expression observed during obesity. The gene discussed is FMO5; the disease is obesity disorder.